Human Genome Epidemiology Literature Finder
|
Records 1 - 26 (of 26 Records) |
| Query Trace: Lung Neoplasms and CYP1A2[original query] |
|---|
| Cytochrome P4501A2 (CYP1A2) activity and lung cancer risk: a preliminary study among Chinese women in Singapore. Carcinogenesis 2001 Apr 22 (4): 673-7. Seow A, Zhao B, Lee EJ, Poh WT, Teh M, Eng P, Wang YT, Tan WC, Lee HP |
| Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer. Alcoholism, clinical and experimental research 2002 Aug 26 (8 Suppl): 15S-19S. Itoga Sakae, Nomura Fumio, Makino Yasuhiko, Tomonaga Takeshi, Shimada Hideaki, Ochiai Takenori, Iizasa Toshihiko, Baba Masayuki, Fujisawa Takehiko, Harada Sho |
| NAT2 fast acetylator genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan. Cancer letters 2005 Jun 223 (1): 93-101. Chiou Hui-Ling, Wu Ming-Fang, Chien Wen-Pin, Cheng Ya-Wen, Wong Ruey-Hong, Chen Chin-Yi, Lin Torng-Sen, Lee Hu |
| NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pacific journal of cancer prevention : APJCP 0 8 (1): 103-8. Osawa Yasunori, Osawa Kayo Kumar, Miyaishi Aiko, Higuchi Miho, Tsutou Akimitsu, Matsumura Sueo, Tabuchi Yoshiki, Tsubota Noriaki, Takahashi Ju |
| Interaction between CYP1A2-T2467DELT polymorphism and smoking in adenocarcinoma and squamous cell carcinoma of the lung. Lung cancer (Amsterdam, Netherlands) 2007 Sep 57 (3): 266-72. Pavanello Sofia, B'chir Fatma, Pulliero Alessandra, Saguem Saâd, Ben Fraj Radhia, El Aziz Hayouni Abed, Clonfero Erminio, Mastrangelo Giusep |
| Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 2007 Jun 28 (6): 1287-93. Gemignani Federica, Landi Stefano, Szeszenia-Dabrowska Neonilia, Zaridze David, Lissowska Jolanta, Rudnai Peter, Fabianova Eleonora, Mates Dana, Foretova Lenka, Janout Vladimir, Bencko Vladimir, Gaborieau Valérie, Gioia-Patricola Lydie, Bellini Ilaria, Barale Roberto, Canzian Federico, Hall Janet, Boffetta Paolo, Hung Rayjean J, Brennan Pa |
| CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life sciences 2009 May 84 (21-22): 779-84. B'chir Fatma, Pavanello Sofia, Knani Jalel, Boughattas Sami, Arnaud Maurice J, Saguem Sa |
| CYP1A1/2 haplotypes and lung cancer and assessment of confounding by population stratification. Cancer research 2009 Mar 69 (6): 2340-8. Aldrich Melinda C, Selvin Steve, Hansen Helen M, Barcellos Lisa F, Wrensch Margaret R, Sison Jennette D, Kelsey Karl T, Buffler Patricia A, Quesenberry Charles P, Seldin Michael F, Wiencke John |
| Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer biomarkers : section A of Disease markers 2011 11 8 (6): 351-9. Singh Arvind P, Pant Mohan C, Ruwali Munindra, Shah Parag P, Prasad Rajendra, Mathur Neeraj, Parmar Devend |
| Role of CYP1A2 polymorphisms on lung cancer risk in a prospective study. Cancer genetics 2012 Jun 205 (6): 278-84. Pavanello Sofia, Fedeli Ugo, Mastrangelo Giuseppe, Rota Federica, Overvad Kim, Raaschou-Nielsen Ole, Tjønneland Anne, Vogel Ul |
| Haplotypes in the 5'-untranslated region of the CYP1A2 gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism. Environmental and molecular mutagenesis 2013 Mar 54 (2): 124-32. Gervasini Guillermo, Ghotbi Roza, Aklillu Eleni, San Jose Carmen, Cabanillas Agustin, Kishikawa Junko, Benitez Julio, Carrillo Juan Anton |
| Meta-analysis of the CYP1A2 -163C>A polymorphism and lung cancer risk. Asian Pacific journal of cancer prevention : APJCP 2013 14 (5): 3155-8. Deng Sheng-Qiong, Zeng Xian-Tao, Wang Yun, Ke Qing, Xu Qiong- |
| Current evidence on the relationship between three polymorphisms in the CYP1A2 gene and the risk of cancer. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2013 Nov 22 (6): 607-19. Zhenzhen Li, Xianghua Liu, Ning Sun, Zhan Guo, Chuanchuan Ren, Jie |
| CYP1A2 rs762551 polymorphism contributes to risk of lung cancer: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014 Mar 35 (3): 2253-7. Ma Zheng, Guo Wei, Gong Taiqian, Niu Hui-Jun, Wang Ru-Wen, Jiang Yao-Gua |
| Four polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene and lung cancer risk: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP 2014 15 (14): 5673-9. Bu Zhi-Bin, Ye Meng, Cheng Yun, Wu Wan-Zh |
| [Evaluation of connection of combinations of polymorphic variants of genes of xenobiotic metabolizing enzymes with a predisposition to lung cancer]. T?Sitologii?a i genetika 0 48 (2): 52-9. Mikhalenko E P, Krupnova É V, Chakova N N, Chebotareva N V, Demidchik Iu |
| Association between the CYP1A2 polymorphisms and risk of cancer: a meta-analysis. Molecular genetics and genomics : MGG 2015 Apr 290 (2): 709-25. Sun Wen-Xia, Chen Ying-Hua, Liu Zhi-Zhong, Xie Jian-Jun, Wang Wei, Du Ya-Ping, Chen Yu, Shen Xu-Liang, He Xiao-Feng, Wu Li-Xia, Wei Wu, Zhang L |
| Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects. Clinical drug investigation 2015 Jan 35 (1): 31-43. Choi Hyun-Gyu, Jeon Ji-Young, Im Yong-Jin, Kim Yunjeong, Song Eun-Kee, Seo Young-Hwan, Cho Seok-Je, Kim Min-G |
| CYP1A2 rs2069514 polymorphism and lung cancer susceptibility: a meta-analysis. Annals of translational medicine 2015 May 3 (7): 93. Shao Wenlong, He Jianxi |
| Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers. Current drug metabolism 2015 16 (10): 850-63. He Xin, Feng Sh |
| Meta-analysis of correlation between the CYP1A2 -3860 G > A polymorphism and lung cancer risk. Genetics and molecular research : GMR 2016 Jun 15 (2): . Ren J, He B Z, Zhang T S, Lu S P, Yan |
| Associations of CYP1A2 Polymorphisms with the Risk Haplotypes in Lung Cancer in the Slovak Population. Advances in experimental medicine and biology 2016 Mar . Matakova T, Halasova E, Dzian A, Hruby R, Halasa M, Javorka K, Skerenova |
| Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters. Biological & pharmaceutical bulletin 2018 41 (1): 47-56. Endo-Tsukude Chihiro, Sasaki Ji-Ichiro, Saeki Sho, Iwamoto Norihiro, Inaba Megumi, Ushijima Sunao, Kishi Hiroto, Fujii Shinji, Semba Hiroshi, Kashiwabara Kosuke, Tsubata Yukari, Hayashi Mitsuhiro, Kai Yuki, Saito Hideyuki, Isobe Takeshi, Kohrogi Hirotsugu, Hamada Akino |
| Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients. Frontiers in pharmacology 2020 11 664. Liao Dehua, Liu Zhigang, Zhang Yongchang, Liu Ni, Yao Dunwu, Cao Lizhi, Chen Yun, Fu Yilan, Yang Nong, Xiang Daxio |
| Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer. Frontiers in pharmacology 2022 13 918219. Tan Tingfei, Han Gongwei, Cheng Ziwei, Jiang Jiemei, Zhang Li, Xia Zitong, Wang Xinmeng, Xia Qu |
| CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients. Frontiers in pharmacology 2023 11 14 1222435. Teerapat Majam, Chonlaphat Sukasem, Thanyanan Reungwetwattana, Phichai Chansriwong, Chalirmporn Atasilp, Narumol Trachu, Thanaporn Thamrongjirapat, Rattanaporn Sukprasong, Jennis Meanwattha |
- Page last reviewed:Feb 1, 2024
- Content source: